1. Home
  2. PAYO vs LQDA Comparison

PAYO vs LQDA Comparison

Compare PAYO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Payoneer Global Inc.

PAYO

Payoneer Global Inc.

HOLD

Current Price

$5.68

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$33.95

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAYO
LQDA
Founded
2005
2004
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PAYO
LQDA
Price
$5.68
$33.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
10
Target Price
$9.79
$37.40
AVG Volume (30 Days)
2.8M
2.0M
Earning Date
11-05-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.18
N/A
Revenue
$1,039,820,000.00
$69,216,000.00
Revenue This Year
$11.18
$904.79
Revenue Next Year
$7.45
$188.25
P/E Ratio
$31.18
N/A
Revenue Growth
10.58
343.41
52 Week Low
$4.92
$10.37
52 Week High
$11.19
$34.02

Technical Indicators

Market Signals
Indicator
PAYO
LQDA
Relative Strength Index (RSI) 49.24 69.52
Support Level $5.65 $30.50
Resistance Level $5.87 $32.80
Average True Range (ATR) 0.17 1.82
MACD 0.04 0.31
Stochastic Oscillator 65.74 99.22

Price Performance

Historical Comparison
PAYO
LQDA

About PAYO Payoneer Global Inc.

Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: